1 Min Read
April 28 (Reuters) - Lupin Ltd
* Lupin clarifies on news item, “Lupin’s Goa plant receives adverse FDA observations”.
* Lupin clarifies that USFDA issued form 483 citing 3 observations Source text: (bit.ly/2qdPeIM) Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.